Executive Director
BMS, New Jersey, United States
Mandy Xie, Executive Director for Cell Therapy Product & Analytical Development in BMS, has extensive experience on CMC development from Biologics, mRNA vaccine to Cell Therapy. She has PhD on Analytical Chemistry and has been devoted her career on technical development to define the integrated control strategies from IND to BLA. In her current role, she leads a scientific and operational organization to develop and execute the control strategy for Autologous CAR-T and gene-edited Allogenic products from preIND to commerical stage.
Disclosure information not submitted.
Wednesday, April 26, 2023
9:00 AM – 9:30 AM ET